Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: MS Clear all
Not listed Phase 2 Interventional Results available

Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

NCT04742400
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
tolebrutinib 60mg, tolebrutinib 120mg
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Methylphenidate to Improve Balance and Walking in MS

NCT01896700
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis

NCT02710214
View directory record Official record
Conditions
Menopause, Multiple Sclerosis
Interventions
Tissue Selective Estrogen Complex, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 62 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Sep 4, 2026, 7:55 PM EDT
Completed No phase listed Observational

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

NCT00490906
View directory record Official record
Conditions
Multiple Sclerosis, Low Bone Density
Interventions
Copaxone, Interferon-beta 1a, Interferon-beta 1b
Drug
Lead sponsor
Nancy Hammond, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Phase 2 Interventional

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

NCT04002934
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Bazedoxifene Acetate
Drug
Lead sponsor
Riley Bove, MD
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Phase 4 Interventional Results available

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

NCT03135249
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Alemtuzumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Phase 4 Interventional Results available

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

NCT01216072
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Fingolimod, Standard MS DMTs
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
142
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®

NCT00239993
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
glatiramer acetate, Warm compress prior to injection of glatiramer acetate
Drug · Procedure
Lead sponsor
Teva Neuroscience, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Fullerton, California • Miami, Florida • Springfield, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Phase 3 Interventional

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

NCT01844232
View directory record Official record
Conditions
Multiple Sclerosis, Spasticity
Interventions
arbaclofen
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Gilbert, Arizona • Phoenix, Arizona • Pasadena, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 4, 2026, 7:55 PM EDT
Recruiting Phase 2 Interventional

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

NCT07497399
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
NLY01, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

NCT00573443
View directory record Official record
Conditions
Pseudobulbar Affect (PBA)
Interventions
dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
45
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 4, 2026, 7:55 PM EDT
Suspended No phase listed Observational

Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis

NCT05949580
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
MS Care Platform (icobrain ms and icompanion ms)
Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Golden Valley, Minnesota • Hackensack, New Jersey • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Repetitive Transcranial Magnetic Stimulation on Resting State Brain Activity in Schizophrenia

NCT01620086
View directory record Official record
Conditions
Schizophrenia
Interventions
Active Repetitive Transcranial Magnetic Stimulation 1 Hz, Active Repetitive Transcranial Magnetic Stimulation 10 Hz, Active control site Repetitive Transcranial Magnetic Stimulation at 1Hz, Sham control site Repetitive Transcranial Magnetic Stimulation, Active control site Repetitive Transcranial Magnetic Stimulation at 10 Hz
Device
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis

NCT00432900
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
[(11)C]PBR28
Radiation
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 4, 2026, 7:55 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839

NCT02306811
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Vatelizumab
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Cullman, Alabama • Fort Collins, Colorado • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

Rebif New Formulation (RNF) Quality of Life (QOL) Study

NCT00472797
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Rebif New Formulation Non Titrated, Rebif New Formulation Titrated
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Phase 1 Interventional Results available

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

NCT04602390
View directory record Official record
Conditions
Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
Interventions
ANK-700, Placebo
Drug
Lead sponsor
Anokion SA
Industry
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
Cullman, Alabama • Phoenix, Arizona • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 4, 2026, 7:55 PM EDT
Not listed Not applicable Interventional

Computerized Cognitive Exercise Training Treatment for Adults With Multiple Sclerosis

NCT02141386
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation)
Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 4, 2026, 7:55 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT04926818
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 4, 2026, 7:55 PM EDT
Not listed Not applicable Interventional

Testing the Efficacy of Self-Generation Treatment Protocol

NCT02032589
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Self-generation treatment
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Not applicable Interventional

Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation in Patients With Multiple Sclerosis

NCT02065284
View directory record Official record
Conditions
Multiple Sclerosis, Ambulation Difficulty
Interventions
Rhythmic Auditory Stimulation (RAS)
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Not applicable Interventional Results available

Cognitive Markers in Prodromal MS

NCT05543915
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Active tDCS
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
23 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 4, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

Aspirin for Exercise in Multiple Sclerosis (ASPIRE)

NCT03824938
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Aspirin 650mg Oral Capsule, Acetaminophen Tablet 650mg, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 4, 2026, 7:55 PM EDT
Not yet recruiting Phase 3 Interventional

Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project

NCT07472413
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cetirizine, Diphenhydramine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 4, 2026, 7:55 PM EDT